Abstracts tagged "epidemiologic methods and human leukocyte antigens (HLA)"

Abstract Number: 1975 • 2018 ACR/ARHP Annual Meeting
Behcet’s Disease Lies in the “B” Holder. New Associations in Disease Susceptibility and Manifestations
Mohanad Elfishawi^1,2, Sally Elfishawi³, Ghada Mossallam³, Paul Norman⁴, Jill Hollenbach⁵, Maneesh Misra⁵, Gonzalo Montero Martin⁶, Helma de Bruin⁷, Leos Van de Pasch⁷, Erik Rozemuller⁷, Marcelo Fernandiz-Vina⁶, Adriana Abrudescu⁸ and Khaled Zaky⁹, ¹Internal Medicine, Icahn School of Medicine at Mount Sinai, Queens Hospital Center, New York, NY, ²Rheumatology, Kasr Alainy Hospital, Cairo University, Cairo, Egypt, ³Clinical pathology and Immunology laboatory, National Cancer Institute, Cairo University, Cairo, Egypt, ⁴Division of Personalized Medicine and Department of Immunology, University of Colorado School of Medicine, Denver, CO, ⁵Department of Neurology, University of California San Francisco, San Francisco, CA, ⁶Department of Pathology, Stanford University,School of medicine, Palo Alto, CA, ⁷GenDx, Utrecht, Netherlands, ⁸Internal Medicine and Rheumatology, Icahn School of Medicine at Mount Sinai, Queens Hospital center, NYC, NY, ⁹Rheumatology and Rehabilitation, Faculty of medicine, Al-Azhar University, Cairo, Egypt
Background/Purpose: Behçet’s disease is a multisystem disease affecting young adults with variable vessel vasculitis as its underlying pathology. Previous studies in Behçet’s disease linked it…

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.